Live vaccine risk in immunocompromised patients

The Therapeutic Goods Administration (TGA) has reminded health professionals that Zostavax vaccine should not be used in immunocompromised patients due to the risk of disseminated disease from the virus. The TGA alert follows the death of a person with pre-existing compromised immune function who received the live, attenuated varicella-zoster virus vaccine. Zostavax has a much ...

Already a member?

Login to keep reading.

© 2021 the limbic